Molecular Diagnostic Company Genetic Technologies Limited (ASX: GTG) is an ASX and NASDAQ (GENE) listed company with specialization in women’s health through its predictive testing and assessment tools. Its product BREVAGenplus® helps in assessing non-hereditary breast cancer. It is marketed to healthcare professionals at breast healthcare and imaging centres.
Today, on March 20, 2019, Genetic Technologies announced investor presentation report. The company has 20 years of experience in bringing genomics products to the market. It is currently developing and commercialising a suite of genetic risk assessment products to prevent morbidity and mortality across a range of diseases. It has a progressive R&D and commercialisation partnership with the universities, research organisations and companies exploring new delivery technologies for genomic solutions.
Genetic Technologies has two corporate centres i.e. Genetic Technologies Limited Melbourne, Victoria, Australia and Phenogen Sciences Inc. Charlotte, North Carolina, U.S.
Its Australian centre has technical and corporate support facilities with the laboratory globally certified to RCPA, CLIA, NATA, and ISO. Its United States centre comprised of sales and marketing, customer support, reimbursement management and sample accessioning to Laboratory Information Management System in Australia.
BREVAGenplus® involves a simple cheek swab-based test, which helps in determining women’s risk of developing sporadic breast cancer. It is a first test of its kind as it is clinically validated, which evaluates risk for sporadic breast cancer. It is CLIA-approved and be used in Caucasian, Hispanic and African-American women aged more than 35.
As per the report, one in eight women will suffer breast cancer in their lifetime. 15% of the breast cancers are hereditary with 5% to 10% of breast cancers caused by BRCA1/BRCA2 mutations or 5% to 10% are unknown hereditary cancers. Rest 85% of breast cancer cases are non-hereditary (sporadic) with less than 15% of women who get breast cancer have a family history and only half will test positive for the BRCA mutation. Genetic Technologies’ enhanced breast cancer test covers all non-BRCA related cancers.
Its breast cancer risk assessment test offers the potential for more efficient use of screening resources, such as mammography and MRI, through precision genetic risk profiling across the entire population of women. As per the report, screening programs that test all women at the same intervals will be over-screening seven women and underscreening one woman.
Every year more than 240,000 new breast cancer cases are diagnosed in the U.S., where more than 40,000 patients lose their life. With early detection, more than 95% of such cases can be prevented.
In risk assessment over tumor invasive stages, it is observed that 95% chances of survival for five years with tumors less than 20 mm, 82% chances of survival for tumors between 20mm and 50 mm, and 63% chances of survival for tumors more than 50 mm. Breast cancer develops before it is detected, therefore, it is suggested as “Know Your Risk”. Hence, an early detection results in a better outcome of the treatment.
On stock information, Genetic Technologies’ share last traded at $0.008 on March 20, 2019, with the market capitalisation of ~$21.15 million. Its 52-week high was reported at $0.017 and 52-week low at $0.006 with the average volume of 2,764,012. Its absolute return for five years, one year and three months are -86.67%, -30.43%, and 33.33%, respectively.